CORDLIFE GROUP LIMITED
(Company Registration No.: 200102883E)
(Incorporated in the Republic of Singapore)

UPDATE ON CLAIMS AGAINST THE COMPANY

The Board of Directors (the "**Board**") of Cordlife Group Limited (the "**Company**") and together with its subsidiaries, the "**Group**") refers to the announcements dated 2 May 2024 and 15 August 2024, outlining, among others, the status of claims against the Company by clients of the Company alleging the damage of cord blood units resulting from the Company's storage of the cord blood units ("**Allegations**").

Unless otherwise stated herein, all capitalised terms shall have the same meanings set out in the aforementioned announcements.

The Company wishes to update that in addition to the Letter of Demand disclosed in the Company's announcement dated 2 May 2024, the Company has continued to receive claims from clients substantially relating to the Allegations, and some of which are currently lodged against the Company in the Small Claims Tribunal.[1] As of the date of this Announcement, some of these claims have been voluntarily discontinued by the clients and one claim was dismissed by the Small Claims Tribunal. In February 2025, the Company has also received correspondence sent on behalf of persons who have identified themselves as the Company's clients in relation to the Company's cryopreservation and storage of cord blood units for their children. In particular, it was informed, *inter alia*, that they are in the process of assessing the losses suffered by such persons by reason of the Company's alleged breaches of contract, negligence and misrepresentation. The Company is in the process of seeking legal advice and will appropriately respond to the Company's clients in due course.

The Company is, in consultation with its legal advisers, actively monitoring and attending to the abovementioned matters and will take necessary steps to engage with relevant parties at the appropriate juncture. The status of those claims remains subject to change and further determination with the relevant parties. As the exposure from such claims remains uncertain, the Company is unable to determine the impact of such claims on the Group's financial performance and prospects for the financial year ending 31 December 2025. However, should the Company be ultimately required to settle all the claims made by multiple clients, this will likely result in a negative impact on the financial position of the Group for the financial year ending 31 December 2025.

The Company will continue to update its shareholders if there are any material developments on the above, in accordance with the listing rules of the Singapore Exchange Securities Trading Limited. In the meantime, shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the actions they should take.

For and on behalf of the Board
CORDLIFE GROUP LIMITED

Cheok Hui Yee
Goh Xun Er
Company Secretaries

1 March 2025

[1] As mentioned in the Company's announcement dated 2 May 2024, the Small Claims Tribunal has the jurisdiction to deal with claims not exceeding S$20,000 (or S$30,000 but only if there is a Memorandum of Consent signed by both parties, which is not the case in respect of the claims received by the Company).